EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

5‐Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S‐1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1)

Shuichi Mitsunaga iD, Masafumi Ikeda, Shogo Nomura, Chigusa Morizane, Akiko Todaka, Naoto Yamamoto, Ken Kamata iD, Hiroo Yanagibashi, Nobumasa Mizuno, Yasuyuki Kawamoto, Kunihito Gotoh, Hirofumi Shirakawa und 19 weitere

Journal of Hepato-Biliary-Pancreatic Sciences · 2024

DOI: 10.1002/jhbp.12071 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2024. Verfasst von Shuichi Mitsunaga und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Tegafur, Oxonic Acid, Fluorouracil, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, the Health and Labor Sciences Research Expenses for Commission, and the Applied Research for Innovative Treatment of Cancer from the Ministry of Health, Labor,…, the National Cancer Center Research and Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

S‐1, an oral fluoropyrimidine derivative, is standard adjuvant therapy for resected biliary tract cancer (BTC), based on the results of the JCOG1202, a phase III trial evaluating the survival benefit with adjuvant S‐1 following curative resection for BTC compared to surgery alone. This multicenter ancillary study of the JCOG1202 aimed to evaluate the prognostic impact of the 5‐fluorouracil (5‐FU) metabolic pathway genes including thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD).

Methods

The 5‐FU metabolic pathway genes were measured in tumor cells from formalin‐fixed paraffin‐embedded resected specimens from 183 patients (surgery alone: n = 94; adjuvant S‐1: n = 89). We randomly divided them into training ( n = 96) and validation sets ( n = 87) for evaluating the interaction between gene levels and RFS benefits in the treatment arm.

Results

RFS benefits of adjuvant S‐1 were observed in the low DPD (HR = 0.440 and 0.748, respectively in the training and validation sets) and the low TP groups (HR = 0.709 and 0.602, respectively). Clinicopathological characteristics were well balanced between low and high DPD populations. More advanced stage tumors were observed in high TP populations as compared to those in low TP populations ( p = .0332).

Conclusion

The results suggest the RFS benefit of adjuvant S‐1 in resected BTC patients with low DPD and low TP gene expressions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TegafurOxonic AcidFluorouracilAntimetabolites, AntineoplasticDrug CombinationsBiliary Tract NeoplasmsNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedChemotherapy, AdjuvantDihydrouracil Dehydrogenase (NADP)PrognosisThymidine PhosphorylaseRisk AssessmentMetabolic Networks and Pathways

Stichwörter der Autor:innen

5‐FU metabolic pathwayDPDS‐1adjuvantbiliary tract cancer

Substanzen

TegafurOxonic AcidS 1 (combination)FluorouracilAntimetabolites, AntineoplasticDrug CombinationsDihydrouracil Dehydrogenase (NADP)Thymidine Phosphorylase

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Division of Biomarker Discovery, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
  • JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto, Japan.
  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.

ORCID-Profile: Shuichi Mitsunaga, Ken Kamata, Naohiro Okano, Kazunari Tanaka, Haruo Miwa

Förderung

  • Japan Agency for Medical Research and Development
  • the Health and Labor Sciences Research Expenses for Commission, and the Applied Research for Innovative Treatment of Cancer from the Ministry of Health, Labor,…
  • the National Cancer Center Research and Development Fund

Zitieren

APA

Mitsunaga, S., Ikeda, M., Nomura, S., Morizane, C., Todaka, A., Yamamoto, N., Kamata, K., Yanagibashi, H., Mizuno, N., Kawamoto, Y., Gotoh, K., Shirakawa, H., Okano, N., Nomura, T., Tanaka, K., Takahashi, A., Yagi, S., Ohta, K., Takayama, Y., …, & Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG‐HBPOG) (2024). 5‐Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S‐1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1). Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.12071

Vancouver

Mitsunaga S, Ikeda M, Nomura S, Morizane C, Todaka A, Yamamoto N, et al. 5‐Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S‐1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1). Journal of Hepato-Biliary-Pancreatic Sciences. 2024. doi:10.1002/jhbp.12071

BibTeX
@article{Mitsunaga2024,
  author = {Mitsunaga, Shuichi and Ikeda, Masafumi and Nomura, Shogo and Morizane, Chigusa and Todaka, Akiko and Yamamoto, Naoto and Kamata, Ken and Yanagibashi, Hiroo and Mizuno, Nobumasa and Kawamoto, Yasuyuki and Gotoh, Kunihito and Shirakawa, Hirofumi and Okano, Naohiro and Nomura, Tatsuya and Tanaka, Kazunari and Takahashi, Amane and Yagi, Shintaro and Ohta, Koji and Takayama, Yukiko and Miwa, Haruo and Nagano, Hiroaki and Kojima, Yasushi and Hisano, Terumasa and Tahara, Munenori and Sakuma, Yasunaru and Arai, Hiroyuki and Nakamura, Ikuo and Katayama, Hiroshi and Konishi, Masaru and Ueno, Makoto and Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG‐HBPOG), Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG‐HBPOG)},
  title = {5‐Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S‐1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1)},
  journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
  year = {2024},
  doi = {10.1002/jhbp.12071}
}
Kostenlos starten →